IMPT for Reproductive Health

The Supporting Agency Collaboration Committee (SACC)

MPT Priority Action Areas & Gaps

As of September 2022, the priority **MPT Fieldwide Action Areas** identified by the SACC are as follows:

1. **A productive ecosystem of MPT product R&D**
   - Ecosystem expansion - Part 1: Expanding MPT R&D with a focus on new products
     - Expanded pipeline of researchers for expanded product R&D
     - Enhanced physical infrastructure for product R&D
     - Geographic expansion for MPT R&D in terms of primary researchers and collaborative efforts
     - Expanded generic licensing opportunities and geographically broad manufacturing base
   - Ecosystem expansion - Part 2: Achieving appropriate funding to support necessary expansion of MPT ecosystem
     - Novel and innovative funding and investment approaches to ensure successful development of MPTs through commercialization and scale-up
     - Enhanced ability for cost-effective collaborations
2. **Improved understanding of reproductive biology for the purpose of new pharmaceutical development for MPT R&D**
   - Enhanced focus on non-hormonal MPTs
   - Enhanced focus on male contraceptive options
   - Expanded understanding of cervicovaginal microbiome, pharmacogenomics, etc.
   - Expanded understanding of underlying conditions in those likely to use MPTs (e.g., perimenopause, cognitive disabilities, other underlying health issues)
3. **Expanded understanding of socio-behavioral research (SBR) considerations among underrepresented groups in MPT research, including**
   - People under the age of 18
   - People with gynecological conditions
   - Sexual and gender minority (SGM) populations
   - Older populations (e.g., perimenopausal women)
   - Those known to metabolize drugs differently (e.g., obese individuals, Down syndrome individuals)
4. **Expanded understanding of market considerations to help ensure successful commercialization and uptake of MPTs, including**
   - Market segmentation and target segment identification
   - Switching between products and triggers estimates
   - Demand forecasting
5. **Enhanced understanding of innovative approaches for MPT clinical trials that address regulatory and ethical challenges of testing multiple indications in the same trial**